Stock of the Day

Liquidia (LQDA)

$18.45

+$0.43 (+2.4%)

Market Cap: $1.57B

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Recent News

• Liquidia Begins Commercial Rollout Of YUTREPIA For PAH And PH-ILD After FDA Approval (nasdaq.com)
• Stocks To Watch: Liquidia Sees Relative Strength Rating Jump To 93 (msn.com)
• BTIG Raises Liquidia Price Target Following YUTREPIA Approval (msn.com)
• Liquidia Technologies (LQDA) Receives a Buy from LifeSci Capital (theglobeandmail.com)
• Liquidia Shares Rise on Scheduled Commercial Shipment of Yutrepia (marketwatch.com)
• Liquidia stock rises following YUTREPIA shipment news (in.investing.com)
• Liquidia Shares Climb After First Commercial Shipment of YUTREPIA (msn.com)
• Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD (globenewswire.com)